UK View On Arthritic Pain Contested

31 March 1996

The 1995 Uk Medicines Control Agency ruling on the prohibition of advertising of topical products for the treatment of arthritic pain has been contested by the Proprietary Association of Great Britain, which represents the non-prescription drug industry, the prescribing subcommittee of the British Medical Council general Medical Services Committee, the Consumers' Association and the National Consumers' Council.

They have all said that the original consultation was confusing, and that treatment of mild to moderate arthritic pain should be offered to suffers, following a doctor's diagnosis.

On March 22, the MCA issued another consultation (MLX 223), allowing the symptomatic relief of sprains and strains and pain due to nonserious arthritis and rheumatism conditions. The PAGB says while this is a major step, it is still uncertain how "nonserious" wil be interpreted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight